Economic burden of osteoporosis in the world: A systematic review

Kemmak, Asma Rashki; Reazpour, Aziz; Jahangiri, Reza; Nikjoo, Shima; Farabi, Hiro; Soleimanpour, Samira

doi:10.47176/mjiri.34.154

Cited by 56 publications

(62 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By 2020, the number of people suffering from osteoporosis worldwide exceeded 200 million, which will increase rapidly in successive years. The number of annual hip fractures will surpass 3 million, and the cost of treatment is estimated to be 25 billion USD by 2025 [13,271].…”

Section: Conclusion and Future Prospectsmentioning

confidence: 99%

The Effects of Selenium on Bone Health: From Element to Therapeutics

et al. 2022

View full text Add to dashboard Cite

Osteoporosis, characterized by low bone mass and a disruption of bone microarchitecture, is traditionally treated using drugs or lifestyle modifications. Recently, several preclinical and clinical studies have investigated the effects of selenium on bone health, although the results are controversial. Selenium, an important trace element, is required for selenoprotein synthesis and acts crucially for proper growth and skeletal development. However, the intake of an optimum amount of selenium is critical, as both selenium deficiency and toxicity are hazardous for health. In this review, we have systematically analyzed the existing literature in this field to determine whether dietary or serum selenium concentrations are associated with bone health. In addition, the mode of administration of selenium as a supplement for treating bone disease is important. We have also highlighted the importance of using green-synthesized selenium nanoparticles as therapeutics for bone disease. Novel nanobiotechnology will be a bridgehead for clinical applications of trace elements and natural products.

show abstract

Section: Conclusion and Future Prospectsmentioning

confidence: 99%

The Effects of Selenium on Bone Health: From Element to Therapeutics

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Osteoporosis is a systemic metabolic disease characterized by a deteriorated bone microarchitecture, reduced bone mass, and impaired bone strength, resulting in an increased risk of fragility fracture ( Compston et al, 2019 ). Osteoporotic fractures are a major source of morbidity and mortality in the ageing population and place significant medical and economic challenges on the society ( Clynes et al, 2020 ; Rashki Kemmak et al, 2020 ). Because the pathophysiology of osteoporosis is the uncoupling of osteoclasts and osteoblasts, finding novel agents inhibiting bone resorption or stimulating new bone formation is considered a feasible preventive and therapeutic strategy for osteoporosis ( Khosla and Hofbauer, 2017 ; Wang et al, 2017 ; Gennari et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Baohuoside I Inhibits Osteoclastogenesis and Protects Against Ovariectomy-Induced Bone Loss

Fan

Liu

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Bone-resorbing osteoclasts are essential for skeletal remodelling, and the hyperactive formation and function of osteoclasts are common in bone metabolic diseases, especially postmenopausal osteoporosis. Therefore, regulating the osteoclast differentiation is a major therapeutic target in osteoporosis treatment. Icariin has shown potential osteoprotective effects. However, existing studies have reported limited bioavailability of icariin, and the material basis of icariin for anti-osteoporosis is attributed to its metabolites in the body. Here, we compared the effects of icariin and its metabolites (icariside I, baohuoside I, and icaritin) on osteoclastogenesis by high-content screening followed by TRAP staining and identified baohuoside I (BS) with an optimal effect. Then, we evaluated the effects of BS on osteoclast differentiation and bone resorptive activity in both in vivo and in vitro experiments. In an in vitro study, BS inhibited osteoclast formation and bone resorption function in a dose-dependent manner, and the elevated osteoclastic-related genes induced by RANKL, such as NFATc1, cathepsin K, RANK, and TRAP, were also attenuated following BS treatment. In an in vivo study, OVX-induced bone loss could be prevented by BS through interrupting the osteoclast formation and activity in mice. Furthermore, mechanistic investigation demonstrated that BS inhibited osteoclast differentiation by ameliorating the activation of the MAPK and NF-kB pathways and reducing the expression of uPAR. Our study demonstrated that baohuoside I could inhibit osteoclast differentiation and protect bone loss following ovariectomy.

show abstract

“…Osteoporosis is one of the main threats of aging, and its prevalence among people aged over 50 years is 30% in women and 15% in men. Osteoporosis is characterized by a decrease in bone mineral content along with bone matrix, so that bone loss is reduced, but bone composition remains normal (1). Osteoporosis is preventable and treatable, but since it is a latent disease, it is usually undetectable until the final stages (2).…”

Section: Introductionmentioning

confidence: 99%

Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review

Nargesi¹,

Barghazan²,

Sani'ee³

et al. 2022

ijph

View full text Add to dashboard Cite

Background: We aimed to review the systematic economic evaluation of denosumab versus than alternative drugs and oral bisphosphonates of postmenopausal osteoporosis in women and help health system policy makers for prioritizing and optimally allocate limited health resources. Methods: We examined the databases of PubMed, Web of Science, Embase, Scopus, Cochrane Library, ProQuest. Strategy search was designed based on keywords. Inclusion criteria were: studies that conducted economic evaluation denosumab compared to oral bisphosphonates for the treatment of osteoporosis in postmenopausal women. Cost-effectiveness studies conducted using decision analysis models based on the economic evaluation approach; studies with available full-text papers; and studies written in English and published between 2010 and 2020. After selecting articles based on inclusion and exclusion criteria, data were extracted and the results were summarized. The quality of the articles was evaluated using the CHEERS checklist. Results: Among 214 initial studies, 8 studies met the inclusion criteria. Most studies focused on the cost-effectiveness of denosumab compared with oral bisphosphonates for the treatment of osteoporosis. The study agreed interval ranged from 3 months to 5 years. The costs investigated in the studies were direct medical costs. In most studies, the use of denosumab significantly prevented fractures. Conclusion: Denosumab is generally more cost-effective than alternative drugs and oral bisphosphonates (alendronate, risedronate, strontium ranelate, ibandronate, and untreated).

show abstract

Economic burden of osteoporosis in the world: A systematic review

Cited by 56 publications

References 0 publications

The Effects of Selenium on Bone Health: From Element to Therapeutics

The Effects of Selenium on Bone Health: From Element to Therapeutics

Baohuoside I Inhibits Osteoclastogenesis and Protects Against Ovariectomy-Induced Bone Loss

Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review

Contact Info

Product

Resources

About